Q-ANTIACNE GEL | Crassula Cosmeceutical
Powered by QuanticSphere™ PQNS Technology

Q-Antiacne
Gel

A Multi-Target, Non-Antibiotic Topical Therapy for Mild-to-Moderate Acne Vulgaris.
Prepared for: Crassula Cosmeceutical Division

"Clinical precision for acne control. Antibiotic-free."

Q-ANTIACNE Gel
0%
Erythema Reduction
by Day 28
0%
Sebum / Oiliness Reduction
by Day 28
0%
PIH Improvement
Progressive visible reduction
60
Patients in the
Clinical Study

Addressing the Clinical Burden
of Acne Vulgaris

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit with substantial clinical, psychosocial, and economic burden. Existing topical therapies—particularly antibiotics, benzoyl peroxide, and retinoids—are effective but limited by irritation, antimicrobial resistance, and poor long-term adherence.

Q-ANTIACNE Gel is a scientific-grade, non-antibiotic, non-steroidal topical formulation designed to address all four core pathogenic drivers of acne:

Microbial overgrowth
Inflammation
Excess sebum & follicular hyperkeratinization
Post-inflammatory tissue damage and scarring

Rapid, Statistically & Clinically Meaningful Improvement

Clinical evaluation in 60 patients with mild-to-moderate acne vulgaris demonstrated rapid, statistically and clinically meaningful improvement within 14 days, with sustained outcomes at 28 days and excellent tolerability.

Prospective · Open-label · Single-arm clinical evaluation · Ages 15–35 · Q-ANTIACNE Gel applied twice daily for 28 days

Scientific Basis

Acne vulgaris arises from a convergence of four mechanisms. Unlike monotherapy approaches, Q-ANTIACNE is engineered as a multi-pathway intervention, interrupting acne progression at multiple biological checkpoints simultaneously.

01
Sebaceous hyperactivity
Under androgenic stimulation → increased sebum production and follicular obstruction.
02
Follicular hyperkeratinization
→ Microcomedone formation blocking the pilosebaceous canal.
03
Colonization by C. acnes
Cutibacterium acnes and related microbes proliferating in the sebaceous environment.
04
Inflammatory cascade activation
TLR-2, NF-κB, IL-1β, TNF-α — generating persistent erythema and edema.

Mechanism of Action

Terpinen-4-ol (Tea Tree)
Disrupts microbial membranes and inhibits C. acnes biofilm formation.
Carvacrol (Oregano)
Broad-spectrum antimicrobial without inducing antibiotic resistance.
Alpha-Monolaurin
Suppresses lipophilic pathogens including C. acnes without resistance induction.

Mechanism →

Disrupt microbial membranes, inhibit biofilm formation, and suppress C. acnes without inducing antibiotic resistance.

TECA (Centella asiatica)
Triterpene complex modulating inflammation and promoting tissue regeneration.
Glycyrrhizin — Licorice extract
Inhibits NF-κB signaling and reduces cytokine-mediated erythema and edema.
Punarnavine — Botanical bioactive
Potent immunomodulatory and anti-inflammatory botanical bioactive.

Mechanism →

Downregulate NF-κB signaling, reduce cytokine-mediated erythema and edema.

Niacinamide
Regulates sebocyte activity and barrier function.
Zinc
Controls sebum production and inflammation.
Vitamin A (retinoid precursor)
Normalizes follicular keratinization and improves barrier integrity.

Mechanism →

Normalize sebocyte activity, reduce follicular plugging, and improve barrier integrity.

Collagen
Promotes fibroblast activity and restores post-lesional dermal architecture.
Hyaluronic Acid
Deep hydration and support of extracellular matrix (ECM) regeneration.
Chondroitin Sulfate + Sepineo DERM complex
ECM regeneration and post-inflammatory hyperpigmentation (PIH) control.

Mechanism →

Promote fibroblast activity, extracellular matrix (ECM) regeneration, and post-inflammatory pigment control.

Advanced Delivery System

Q-ANTIACNE integrates phospholipid-based PQNS vesicles to enhance topical performance. PQNS provides delivery precision without systemic exposure, aligning with medical-grade dermatologic safety standards.

Improved Cutaneous Penetration
Into sebaceous units where active ingredients exert their effect.
Stabilization of Volatile Botanicals
Protecting actives during storage and application.
Controlled Release
With reduced irritation in sensitive and acne-prone skin populations.
Enhanced Dermal Bioavailability
Of lipophilic and hydrophilic actives simultaneously.

Rigorous Clinical Evaluation

ParameterDetail
Study TypeProspective, open-label, single-arm clinical evaluation
Population60 patients (15–35 years) with mild-to-moderate acne vulgaris
Treatment RegimenQ-ANTIACNE Gel applied twice daily for 28 days
Assessment TimepointsDay 0 (baseline), Day 14, Day 28
EndpointsInflammatory lesion count, non-inflammatory lesion count, erythema, oiliness, PIH scores, safety & tolerability
88%
Erythema Reduction
by Day 28
85%
Sebum / Oiliness Reduction
by Day 28
100%
PIH Improvement — Progressive visible reduction
14
Days to rapid, statistically and clinically meaningful improvement

Excellent Safety Profile

No serious adverse events
No serious adverse events reported throughout the full 28-day evaluation period.
Mild, transient dryness or tingling
Reported only in a minority of subjects, self-resolving without treatment discontinuation.
No treatment discontinuations
All subjects completed the full treatment protocol.

This safety profile supports long-term use, including in sensitive and acne-prone skin populations.

Q-ANTIACNE Gel
is positioned as:

1
Scientific grade cosmeceutical
2
Antibiotic-free acne therapy
3
Suitable for adolescents & adults
4
Ideal for inflammatory, hormonal, and recurrent acne
5
Adjunct or alternative to retinoids and antibiotics

Next-Generation
Acne Therapy

Q-ANTIACNE is a scientific-grade cosmeceutical for inflammatory, hormonal, and recurrent acne, combining multi-target action with advanced delivery technology (QuanticSphere™) to deliver clinically effective and well-tolerated acne control without antibiotics.

Contact the Medical Team